ClinicalTrials.gg
Active, not recruitingNCT07201415Updated Oct 1, 2025

Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma

An interventional study of minimally invasive suprachoroidal drainage in Neovascular Glaucoma, sponsored by Zhongnan Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Zhongnan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2025, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

To explore the efficacy and safety of minimally invasive suprachoroidal drainage for the treatment of advanced neovascular glaucoma

Read the detailed description

To explore the efficacy and safety of minimally invasive supraporcular drainage in the treatment of advanced neovascular glaucoma, and to record the various basic diseases, ocular conditions, lifestyle, inflammatory markers and other parameters of NVG patients. To compare the safety and efficacy of new surgical methods and traditional surgical methods in order to find an effective treatment for neovascular glaucoma

02

Conditions studied

  • Neovascular Glaucoma

Keywords

  • Neovascular glaucoma
  • Retinal Vein Occlusion
  • Diabetic Retinopathy
  • Treatment
03

In context

Glaucoma, Neovascular

39 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.

This study's planned enrollment of 30 is below the median of 40 across 32 interventional studies indexed under Glaucoma, Neovascular.

Browse Glaucoma, Neovascular studies →

Lead sponsor

Zhongnan Hospital is the lead sponsor of 106 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced (angle-closure) neovascular glaucoma with poorly controlled intraocular pressure (IOP > 21mmHg) after medical or surgical treatment

Exclusion criteria

Exclusion Criteria:

  • Various other types of glaucoma (including primary open-angle glaucoma, primary open-closed glaucoma, normal tension glaucoma, juvenile glaucoma, congenital glaucoma, other special types of glaucoma, etc.)
  • Eye infection within two weeks before surgery
  • Non-glaucomatous intraocular diseases that affect intraocular pressure (choroidal hemorrhage or detachment, retinal detachment, lens subluxation, thyroid eye disease, macular edema, eye tumors, etc.)
  • Visual acuity of non-study eyes \< 0.05
  • Congenital or acquired factors lead to ciliary body anatomical abnormalities
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Surgical Treatment Group

    The patient will undergo a minimally invasive suprachoroidal drainage procedure

    Procedure: minimally invasive suprachoroidal drainage

Interventions

  • Procedureminimally invasive suprachoroidal drainage

    minimally invasive suprachoroidal drainage

06

What researchers measure

Primary outcomes

  1. Ocular biological parameters

    intraocular pressure

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

  2. Ocular biological parameters

    visual acuity

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

  3. Surgical outcome measures

    use of intraocular pressure lowering drugs

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

  4. The success rate of surgery was evaluated according to the specific value of intraocular pressure after surgery

    Complete success was defined as IOP within the normal range with no drug dependence, conditional success was defined as IOP within the normal range with drug dependence, and failure was defined as the rest

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

Secondary outcomes

  1. The effective rate of surgery was evaluated according to the amplitude of IOP reduction after surgery and the change in the number of IOP-lowering drugs

    Amplitude of IOP reduction: IOP change/initial IOP.The total number of IOP lowering drugs was recorded based on the number of active ingredients

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

  2. Surgical outcome measures

    complications

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Oct 1, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 1, 2027
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07201415
Lead sponsor
Zhongnan Hospital
Responsible party
Sponsor
First posted
Oct 1, 2025
Start date
Jan 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion